Product Datasheet

SGR-1505


Catalog No. **BP-02118** · CAS **2661481-41-8** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-11-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
MALT1; Apoptosis	**Cancer**

Molecular formula	$C_{18}H_{12}ClF_4N_9O$
Molecular weight	**481.7940**

STRUCTURE



DESCRIPTION

SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 can be used for research of B-cell lymphomas.

BIOLOGICAL ACTIVITY

SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas.

SOLUBILITY

Soluble in DMSO : 100 mg/mL

REFERENCES

[1]. Wu Yin PhD, et al. Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile. Volume 142, Supplement 1, 2 November 2023, Page 2997.

[2]. Feng S, et al., Cyclic compounds and methods of using same. WO2021134004.

[3]. Adam Olszewski MD, et al. A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies.Blood. Volume 142, Supplement 1, 2 November 2023, Page 3102.